More recently, Yamashita et al. evaluated the role of IL-6-mediated inflammatory response in the development of post-RP ED by administering Tocilizumab (anti-rat IL-6 antibody) perioperatively in rat model replicas of RP-induced CN lesions. The gene discussed is IL6; the disease is cyclic hematopoiesis.